Alnylam Pharmaceuticals (ALNY)

P/S ratio at the end of 2025: 14.2

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 53.2. At the end of 2025 the company had a P/S ratio of 14.2.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	14.2	4.27%
2024	13.7	3.91%
2023	13.1	-53.38%
2022	28.2	17.32%
2021	24.0	-21.59%
2020	30.6	-47.89%
2019	58.8	-40.29%
2018	98.5	-29.73%
2017	140	105.69%
2016	68.1	-65.05%
2015	195	31.6%
2014	148	70.45%
2013	86.9	505.26%
2012	14.4	241.19%
2011	4.21	0.83%
2010	4.17	-43.09%
2009	7.33	-31.15%
2008	10.7	-54.28%
2007	23.3	-20.88%
2006	29.4	-34.68%
2005	45.1	33.85%
2004	33.7

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Novartis NVS	5.45	-58.33%	🇨🇭 Switzerland
Sanofi SNY	2.26	-82.70%	🇫🇷 France
Regeneron Pharmaceuticals REGN	5.59	-57.24%	🇺🇸 USA
Sarepta Therapeutics SRPT	0.6907	-94.72%	🇺🇸 USA
Regulus Therapeutics RGLS	N/A	N/A	🇺🇸 USA
OPKO Health OPK	1.40	-89.26%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	2.10	-83.96%	🇮🇱 Israel
Arrowhead Pharmaceuticals ARWR	10.0	-23.48%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio at the end of 2025: 14.2